CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, 50134, Florence, Italy.
Department of Experimental and Clinical Medicine, DenoThe Excellence Center, University of Florence, Florence, Italy.
Clin Exp Med. 2020 May;20(2):313-320. doi: 10.1007/s10238-020-00616-5. Epub 2020 Feb 17.
Splenomegaly is a key clinical manifestation of myelofibrosis, and splenectomy is currently indicated in patients with drug refractory, symptomatic splenomegaly or with the aim of improving refractory cytopenias. Transformation to acute myeloid leukemia occurs in up to 20% of patients with myelofibrosis, while cases of myeloid sarcoma have been reported very unfrequently. In this manuscript, we report the case of a 60-year-old man with a history of primary myelofibrosis who underwent splenectomy because of drug-refractory massive splenomegaly, systemic symptoms and anemia. At the opening of the peritoneal cavity, the spleen resulted massively enlarged and tenaciously entrapped by a pervasive neoplastic-like tissue. The extensive involvement of the abdomen fatally complicated the surgical procedure. At postmortem examination, the spleen showed a diffuse infiltration of immature cells that were also found in the peritoneum, bowel, liver, lungs and myocardium. After immunohistochemical, cytogenetic, flow cytometric and molecular characterization of neoplastic population, a diagnosis of disseminated myeloid sarcoma of the spleen was made. This case report highlights a very unusual case of myeloid sarcoma originating from the spleen in a patient with myelofibrosis who had no evidence of bone marrow or peripheral blood involvement by leukemic cells. Molecular characterization showed that leukemic cells originated from the founding clone of the chronic phase. The sarcoma could not be suspected based on clinical findings and was diagnosed only at the time of surgical procedure and autopsy. This case suggests that leukemic transformation of myelofibrosis can originate outside the bone marrow and, presumably rarely, present as a granulocytic sarcoma.
脾肿大是骨髓纤维化的一个重要临床表现,目前脾切除术适用于药物难治性、有症状性脾肿大或旨在改善难治性细胞减少症的患者。高达 20%的骨髓纤维化患者会转化为急性髓系白血病,而骨髓肉瘤的病例则非常罕见。在本文中,我们报告了一例 60 岁男性原发性骨髓纤维化患者的病例,因药物难治性巨脾肿大、全身症状和贫血而行脾切除术。在打开腹腔时,脾脏明显肿大,被广泛的肿瘤样组织紧紧包裹。广泛的腹部受累使手术过程变得复杂。尸检时,脾脏显示出弥漫性不成熟细胞浸润,腹膜、肠道、肝脏、肺和心肌也发现了这些细胞。对肿瘤细胞群进行免疫组织化学、细胞遗传学、流式细胞术和分子特征分析后,诊断为脾弥漫性髓样肉瘤。该病例报告强调了一例非常不寻常的骨髓纤维化患者脾髓样肉瘤病例,该患者无骨髓或外周血白血病细胞受累的证据。分子特征分析表明,白血病细胞起源于慢性期的创始克隆。肉瘤不能仅根据临床发现来怀疑,只能在手术和尸检时诊断。该病例提示骨髓纤维化的白血病转化可起源于骨髓外,推测很少见的情况下表现为粒细胞肉瘤。